{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T05:51:25Z","timestamp":1781675485387,"version":"3.54.5"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To characterize optical coherence tomography (OCT) features of vitreoretinal lymphoma (VRL) at baseline, identify features associated with visual prognosis, and describe longitudinal OCT changes following intravitreal methotrexate (IVT-MTX) treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective, single-center, observational study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Consecutive biopsy-proven VRL cases were included. Spectral-domain OCT (SD-OCT) features were classified into three compartments: sub-retinal pigment epithelium (sub-RPE), subretinal, and intraretinal deposits. Additional features included ellipsoid zone (EZ) disruption, EZ-RPE attenuation, preretinal deposits, and vitreous cells. Patients were stratified as isolated VRL or VRL with concurrent central nervous system involvement (VRL-CNS). Best-corrected visual acuity (BCVA) was analyzed as a continuous variable (logMAR) using generalized estimating equations (GEE) with patient-level clustering, and an exploratory LASSO model was developed to predict significant vision loss (logMAR \u2265 0.5). A subgroup receiving standardized IVT-MTX with longitudinal OCT was analyzed across treatment phases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-eight eyes of 25 patients (14 female; mean age 63.5\u202f\u00b1\u202f12.6\u202fyears) were included over a median follow-up of 14.2\u202fmonths. Sub-RPE deposits were the most prevalent OCT feature (92.1%), followed by subretinal deposits (65.8%) and intraretinal deposits (23.7%). In the multivariable GEE model, baseline BCVA (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.009) and EZ disruption (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.026) were associated with worse visual outcome. In the LASSO model, EZ disruption and EZ-RPE attenuation were selected, and showed an AUC of 0.929 (0.872\u20130.992) for significant vision loss. Twelve eyes of 8 patients comprised the IVT-MTX longitudinal subgroup (mean 7.7\u202f\u00b1\u202f0.8 injections). OCT features showed that vitreous cells resolved rapidly, sub-RPE and subretinal deposits regressed slowly, whereas EZ disruption remained unchanged.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sub-RPE deposits are the most prevalent OCT finding in VRL. EZ disruption and EZ-RPE attenuation are associated with worse visual prognosis. Following IVT-MTX treatment, OCT reveals differential response patterns across lesion compartments, supporting quantitative OCT assessment as a sensitive, noninvasive tool for treatment monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1848089","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:52:04Z","timestamp":1781671924000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Optical coherence tomography features and visual prognosis in vitreoretinal lymphoma: a structured phenotyping study"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaona","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Peking University Third Hospital, Beijing Key Laboratory of Restoration of Damaged Ocular Nerve","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehai","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University Third Hospital, Beijing Key Laboratory of Restoration of Damaged Ocular Nerve","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University Third Hospital, Beijing Key Laboratory of Restoration of Damaged Ocular Nerve","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University Third Hospital, Beijing Key Laboratory of Restoration of Damaged Ocular Nerve","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University Third Hospital, Beijing Key Laboratory of Restoration of Damaged Ocular Nerve","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University Third Hospital, Beijing Key Laboratory of Restoration of Damaged Ocular Nerve","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff","year":"2022","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.3390\/cancers13143479","article-title":"Primary central nervous system lymphoma in elderly patients: management and perspectives","volume":"13","author":"Morales-Martinez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1182\/blood.2020008235","article-title":"Primary vitreoretinal lymphoma: a diagnostic and management challenge","volume":"138","author":"Soussain","year":"2021","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ajo.2021.11.023","article-title":"Advanced OCT analysis of biopsy-proven vitreoretinal lymphoma","volume":"238","author":"Pichi","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/s12886-022-02702-6","article-title":"Epidemiology and survival outcomes of patients with primary intraocular lymphoma: a population-based analysis","volume":"22","author":"He","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1076\/ocii.8.4.243.6463","article-title":"Ocular and central nervous system lymphoma: clinical features and diagnosis","volume":"8","author":"Cassoux","year":"2000","journal-title":"Ocul Immunol Inflamm"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.12809\/hkmj2412293","article-title":"Diagnostic challenges and treatment outcomes of primary vitreoretinal lymphoma in Hong Kong","volume":"32","author":"Chee","year":"2026","journal-title":"Hong Kong Med J"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.ophtha.2020.01.042","article-title":"Logistic regression classification of primary vitreoretinal lymphoma versus uveitis by interleukin 6 and interleukin 10 levels","volume":"127","author":"Kuo","year":"2020","journal-title":"Ophthalmology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.survophthal.2023.12.001","article-title":"Diagnostic methods for primary vitreoretinal lymphoma: a systematic review","volume":"69","author":"Huang","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"10667","DOI":"10.1038\/s41467-025-65693-0","article-title":"A noninvasive machine learning model using a complete blood count for screening of primary vitreoretinal lymphoma","volume":"16","author":"Li","year":"2025","journal-title":"Nat Commun"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00417-025-06949-9","article-title":"Multimodal imaging for diagnosis and follow-up of primary vitreoretinal lymphoma: a systematic review and meta-analysis","volume":"264","author":"Salari","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1136\/bjo.2007.127928","article-title":"Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience","volume":"92","author":"Frenkel","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40942-022-00405-0","article-title":"Multimodal diagnostic imaging in primary vitreoretinal lymphoma","volume":"8","author":"Xu","year":"2022","journal-title":"Int J Retina Vitreous"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12886-019-1300-1","article-title":"Longitudinal observation of OCT imaging is a valuable tool to monitor primary vitreoretinal lymphoma treated with intravitreal injections of methotrexate","volume":"20","author":"Zhao","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12886-022-02604-7","article-title":"Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate","volume":"22","author":"Jiang","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jamaophthalmol.2018.5835","article-title":"Vertical hyperreflective lesions on optical coherence tomography in vitreoretinal lymphoma","volume":"137","author":"De\u00e1k","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/ceo.12685","article-title":"Ellipsoid zone on optical coherence tomography: a review","volume":"44","author":"Tao","year":"2016","journal-title":"Clin Experiment Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/ceo.14197","article-title":"Spectral-domain optical coherence tomography biomarkers in vitreoretinal lymphoma","volume":"51","author":"Guan","year":"2023","journal-title":"Clin Experiment Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41433-021-01657-0","article-title":"A proposed protocol of intravitreal injection of methotrexate for treatment of primary vitreoretinal lymphoma","volume":"36","author":"Zhou","year":"2022","journal-title":"Eye (Lond)"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/IAE.0000000000000409","article-title":"Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration","volume":"35","author":"Broadhead","year":"2015","journal-title":"Retina"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e0203324","DOI":"10.1371\/journal.pone.0203324","article-title":"Assessment of inner and outer retinal layer metrics on the cirrus HD-OCT platform in normal eyes","volume":"13","author":"Arepalli","year":"2018","journal-title":"PLoS One"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.ajo.2013.11.002","article-title":"Neoplastic masquerade syndromes in patients with uveitis","volume":"157","author":"Grange","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.21037\/aol-20-30","article-title":"Treatment of elderly patients with primary CNS lymphoma","volume":"5","author":"Martinez-Calle","year":"2021","journal-title":"Ann Lymphoma"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3892\/ijo.2021.5180","article-title":"Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (review)","volume":"58","author":"Liu","year":"2021","journal-title":"Int J Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/bjh.20115","article-title":"An international real-world study of primary vitreoretinal lymphoma from the Australasian lymphoma alliance and collaborators","volume":"207","author":"Tang","year":"2025","journal-title":"Br J Haematol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.survophthal.2013.12.001","article-title":"Primary intraocular lymphoma","volume":"59","author":"Sagoo","year":"2014","journal-title":"Surv Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"5684","DOI":"10.3390\/ijms12095684","article-title":"Molecular biomarkers for the diagnosis of primary vitreoretinal lymphoma","volume":"12","author":"Wang","year":"2011","journal-title":"Int J Mol Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.oret.2023.10.021","article-title":"Prognosis, risk factors, and clinical features of intraocular recurrence in primary vitreoretinal lymphoma","volume":"8","author":"Liu","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/bjophthalmol-2017-311612","article-title":"Characteristic optical coherence tomography findings in patients with primary vitreoretinal lymphoma: a novel aid to early diagnosis","volume":"102","author":"Barry","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1080\/09273948.2025.2519848","article-title":"Retinal pigment epithelium undulations in primary vitreoretinal lymphoma: an under-recognised OCT biomarker","volume":"33","author":"Chauhan","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/ceo.70067","article-title":"Presenting clinical features of vitreoretinal lymphoma","volume":"54","year":"2026","journal-title":"Clin Experiment Ophthalmol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12886-024-03513-7","article-title":"Optical coherence tomography features in vitreoretinal lymphoma compared with non-infectious uveitis","volume":"24","author":"El Zein","year":"2024","journal-title":"BMC Ophthalmol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/IAE.0000000000002819","article-title":"Spectral domain optical coherence tomography features of vitreoretinal lymphoma in 55 eyes","volume":"41","author":"Yang","year":"2021","journal-title":"Retina"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1080\/09273948.2020.1787460","article-title":"Clinical experience in a large cohort of patients with vitreoretinal lymphoma in a single Center","volume":"29","author":"Giuffr\u00e8","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/09273948.2014.1002568","article-title":"Spectral-domain optical coherence tomography patterns in intraocular lymphoma","volume":"24","author":"Keino","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1097\/IAE.0b013e3182993f66","article-title":"Multimodal imaging of pigment epithelial detachment: a guide to evaluation","volume":"33","author":"Mrejen","year":"2013","journal-title":"Retina"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ophtha.2009.07.014","article-title":"Reticular pseudodrusen are subretinal drusenoid deposits","volume":"117","author":"Zweifel","year":"2010","journal-title":"Ophthalmology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3967\/bes2018.043","article-title":"Optical coherence tomography features of tuberculous serpiginous-like choroiditis and serpiginous choroiditis","volume":"31","author":"Wang","year":"2018","journal-title":"Biomed Environ Sci"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.survophthal.2012.08.008","article-title":"Serpiginous choroiditis and infectious multifocal serpiginoid choroiditis","volume":"58","author":"Nazari Khanamiri","year":"2013","journal-title":"Surv Ophthalmol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0161-6420(02)01737-2","article-title":"Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma","volume":"110","author":"Chan","year":"2003","journal-title":"Ophthalmology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ajo.2025.11.044","article-title":"Retinal pigment epithelium disruption lesions on optical coherence tomography in patients with vitreoretinal lymphoma","volume":"283","author":"Chen","year":"2026","journal-title":"Am J Ophthalmol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1097\/IAE.0000000000003579","article-title":"Perivascular FLOWER-bud-like lesions on EN face optical coherence tomography angiography in patients with vitreoretinal lymphoma","volume":"42","author":"Chen","year":"2022","journal-title":"Retina"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10792-016-0331-3","article-title":"Early deterioration in ellipsoid zone in eyes with non-neovascular age-related macular degeneration","volume":"37","author":"Toprak","year":"2017","journal-title":"Int Ophthalmol"},{"key":"ref45","first-page":"2264","article-title":"Impact of baseline quantitative ellipsoid zone integrity on geographic atrophy expansion in the ReCLAIM-2 clinical trial","volume":"64","author":"Whitmore","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1038\/s41598-023-31414-0","article-title":"Clinical features predictive of vision loss in patients with vitreoretinal lymphoma: a single tertiary center experience","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1848089\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:52:17Z","timestamp":1781671937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1848089\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":47,"alternative-id":["10.3389\/fmed.2026.1848089"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1848089","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"1848089"}}